tetano
Editor, Senior Moderator
Clin Immunol
. 2022 Mar 5;108963.
doi: 10.1016/j.clim.2022.108963. Online ahead of print.
Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine
Matthew K Wong[SUP] 1 [/SUP], Jun T Liu[SUP] 2 [/SUP], Patrick Budylowksi[SUP] 3 [/SUP], Feng Yun Yue[SUP] 2 [/SUP], Zhijie Li[SUP] 4 [/SUP], James M Rini[SUP] 5 [/SUP], James R Carlyle[SUP] 1 [/SUP], Amin Zia[SUP] 6 [/SUP], Mario Ostrowski[SUP] 7 [/SUP], Alberto Martin[SUP] 8 [/SUP]
Affiliations
Abstract
Convalescent coronavirus disease 2019 (COVID-19) subjects who receive BNT162b2 develop robust antibody responses against SARS-CoV-2. However, our understanding of the clonal B cell response pre- and post-vaccination in such individuals is limited. Here we characterized B cell phenotypes and the BCR repertoire after BNT162b2 immunization in two convalescent COVID-19 subjects. BNT162b2 stimulated many B cell clones that were under-represented during SARS-CoV-2 infection. In addition, the vaccine generated B cell clusters with >65% similarity in CDR3 V[SUB]H[/SUB] and V[SUB]L[/SUB] region consensus sequences both within and between subjects. This result suggests that the CDR3 region plays a dominant role adjacent to heavy and light chain V/J pairing in the recognition of the SARS-CoV-2 spike protein. Antigen-specific B cell populations with homology to published SARS-CoV-2 antibody sequences from the CoV-AbDab database were observed in both subjects. These results point towards the development of convergent antibody responses against the virus in different individuals.
Keywords: Antibodies; B cells; COVID19; SARS CoV2.
. 2022 Mar 5;108963.
doi: 10.1016/j.clim.2022.108963. Online ahead of print.
Convergent CDR3 homology amongst Spike-specific antibody responses in convalescent COVID-19 subjects receiving the BNT162b2 vaccine
Matthew K Wong[SUP] 1 [/SUP], Jun T Liu[SUP] 2 [/SUP], Patrick Budylowksi[SUP] 3 [/SUP], Feng Yun Yue[SUP] 2 [/SUP], Zhijie Li[SUP] 4 [/SUP], James M Rini[SUP] 5 [/SUP], James R Carlyle[SUP] 1 [/SUP], Amin Zia[SUP] 6 [/SUP], Mario Ostrowski[SUP] 7 [/SUP], Alberto Martin[SUP] 8 [/SUP]
Affiliations
- PMID: 35259543
- DOI: 10.1016/j.clim.2022.108963
Abstract
Convalescent coronavirus disease 2019 (COVID-19) subjects who receive BNT162b2 develop robust antibody responses against SARS-CoV-2. However, our understanding of the clonal B cell response pre- and post-vaccination in such individuals is limited. Here we characterized B cell phenotypes and the BCR repertoire after BNT162b2 immunization in two convalescent COVID-19 subjects. BNT162b2 stimulated many B cell clones that were under-represented during SARS-CoV-2 infection. In addition, the vaccine generated B cell clusters with >65% similarity in CDR3 V[SUB]H[/SUB] and V[SUB]L[/SUB] region consensus sequences both within and between subjects. This result suggests that the CDR3 region plays a dominant role adjacent to heavy and light chain V/J pairing in the recognition of the SARS-CoV-2 spike protein. Antigen-specific B cell populations with homology to published SARS-CoV-2 antibody sequences from the CoV-AbDab database were observed in both subjects. These results point towards the development of convergent antibody responses against the virus in different individuals.
Keywords: Antibodies; B cells; COVID19; SARS CoV2.